<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083329</url>
  </required_header>
  <id_info>
    <org_study_id>0816302</org_study_id>
    <nct_id>NCT01083329</nct_id>
  </id_info>
  <brief_title>Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects</brief_title>
  <acronym>ANITA</acronym>
  <official_title>Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our working hypothesis postulates that lipolysis is a determinant of inflammation in adipose&#xD;
      tissue (AT). Inhibition of lipolysis, e.g. using the oldest normolipidemic drug, nicotinic&#xD;
      acid, has proved valuable to combat the metabolic syndrome. Our proposal will determine&#xD;
      whether part of the beneficial effects of this antilipolytic compound is due to a diminution&#xD;
      of AT inflammation.&#xD;
&#xD;
      To this aim, the effect of nicotinic acid or placebo will be studied in male obese subjects&#xD;
      with or without a training program which goal is to enhance lipolysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      24 male obese insulin resistant subjects will receive nicotinic acid or placebo for 16 weeks.&#xD;
      The last 8 weeks, the subjects will follow a training program calculated to optimize use of&#xD;
      lipid. Insulin sensitivity and glucose tolerance will be assessed using, respectively,&#xD;
      fasting-based estimates of insulin sensitivity (plasma and muscle) and oral glucose tolerance&#xD;
      test. Plasma parameters of adipokines and, inflammatory and metabolic parameters will be&#xD;
      determined. As an index of AT inflammation, the percentage and the phenotype of macrophages&#xD;
      will be determined using flow cytometry of cells of the stromavascular fraction of&#xD;
      subcutaneous AT. Macrophage infiltration will be investigated by light microscopy. The&#xD;
      characterization of the inflammatory profile of AT will be completed by measurements of the&#xD;
      expression of genes that are either specific markers of human AT macrophages or inflammatory&#xD;
      and anti-inflammatory adipokines. This combination of approaches has never been carried out&#xD;
      during a pharmacological intervention in humans. The following points will be addressed:&#xD;
&#xD;
        -  determine the influence of lipolysis on AT inflammation, specifically on macrophage&#xD;
           activation and adipokine production.&#xD;
&#xD;
        -  examine the causal relationship between adipocyte FA metabolism, AT inflammation and&#xD;
           insulin sensitivity.&#xD;
&#xD;
        -  establish whether the beneficial effect of antilipolytic drugs may be attributable at&#xD;
           least in part to a decrease in AT inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of changes of AT inflammation will be measured by gene expression analysis</measure>
    <time_frame>Visit 1(T0), Visit 2 (T+8 weeks of treatment) and Visit 3 (T+16 weeks of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in insulin sensitivity and glucose tolerance</measure>
    <time_frame>Visit 1(T0), Visit 2 (T+8 weeks of treatment) and Visit 3 (T+16 weeks of treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotinic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>for 16 weeks :&#xD;
week 1 = 375 mg per day,&#xD;
week 2 = 500 mg per day,&#xD;
week 3 = 750 mg per day,&#xD;
week 4 = 1000 mg per day,&#xD;
week 5 = 1500 mg per day,&#xD;
weeks 6 to 16 = 2000 mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>training</intervention_name>
    <description>the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid</description>
    <arm_group_label>nicotinic acid</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotinic acid</intervention_name>
    <description>Obese subjects will receive nicotinic acid or placebo for 16 weeks</description>
    <arm_group_label>nicotinic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Obese subjects will receive nicotinic acid or placebo for 16 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signature of informed consent form&#xD;
&#xD;
          -  Age 25 to 45 year-old&#xD;
&#xD;
          -  Male, insulin resistant obese subjects (30&lt;BMI&lt;40 kg/m2),&#xD;
&#xD;
          -  Blood arterial pressure&lt;140/90 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiovascular disease&#xD;
&#xD;
          -  Treatment with drugs which can interfere with cardiovascular system and autonomic&#xD;
             nervous system (i.e. beta blockers).&#xD;
&#xD;
          -  Treatment with nicotinic acid&#xD;
&#xD;
          -  Treatment with fibrates, statins, cholestyramine and ezetimibe&#xD;
&#xD;
          -  Treatment with thiazidics&#xD;
&#xD;
          -  Fasted hyperglycaemia &gt; 1,26 g/l (Diabetes)&#xD;
&#xD;
          -  Triglycerides &gt;5 g/l&#xD;
&#xD;
          -  Blood arterial pressure &gt; 140/90 mm Hg&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Thalamas</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Toulouse Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, Purpan University Toulouse Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Montastier E, Beuzelin D, Martins F, Mir L, Marqu√©s MA, Thalamas C, Iacovoni J, Langin D, Viguerie N. Niacin induces miR-502-3p expression which impairs insulin sensitivity in human adipocytes. Int J Obes (Lond). 2019 Jul;43(7):1485-1490. doi: 10.1038/s41366-018-0260-5. Epub 2018 Nov 27.</citation>
    <PMID>30482933</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotinic acid</keyword>
  <keyword>lipolysis</keyword>
  <keyword>training program</keyword>
  <keyword>adipose tissue inflammation</keyword>
  <keyword>obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

